

Claims

1. Use of a 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide (velusetrag) or a pharmaceutically acceptable salt thereof in the manufacture of
5 a medicament for treating idiopathic chronic intestinal pseudo-obstruction (CIPO), neuropathic chronic intestinal pseudo-obstruction, or chronic intestinal pseudo-obstruction being secondary to neurodegeneration or being secondary to autoimmune conditions or being secondary to connective tissue disorders or being secondary to demyelinating conditions.
- 10 2. The use of claim 1, wherein the pharmaceutically acceptable salt is a hydrochloride salt.
3. The use of claim 1 or 2, wherein the medicament is in crystalline form and/or hydrated form.
4. The use of one of the claims 1 to 3, wherein the idiopathic CIPO, the neuropathic
15 CIPO or CIPO being secondary to neurodegeneration or being secondary to autoimmune conditions or being secondary to connective tissue disorders or being secondary to demyelinating conditions is one caused by diseases of the autonomic nervous system such as stroke, encephalitis, calcification of basal ganglia, orthostatic hypotension, one caused by diseases of intestinal wall nervous system such as paraneoplastic syndrome, viral
20 infections, iatrogenic disorders, Hirschsprung's disease, Chagas' disease, Von Recklinghausen's disease, one caused by diseases of the intestinal wall muscle layer such as myotonic dystrophy, progressive systemic sclerosis or one caused by diseases of the mixed enteric nervous system and smooth muscle layer such as scleroderma, dermatomyositis, amyloidosis, Ehler-Danlos syndrome or one caused by an unknown
25 mechanism such as hypothyroidism, hypoparathyroidism, pheochromocytoma, antidepressants drugs, antineoplastics or bronchodilators or one caused by immune-mediated and connective tissue disorder or disease such as paraneoplastic disease (CNS neoplasms, lung microstoma, bronchial carcinoid, leiomyosarcomas, systemic lupus erythematosus).
- 30 5. The use of one of claims 1 to 4, wherein the medicament is to treat a patient being an adult or a pediatric patient.

6. The use of claim 5, wherein the patient is one having a history of chronic CIPO or of CIPO secondary to neurodegenerative disease or demyelinating disease.
7. The use of one of claims 1 to 6, wherein at least one of the symptoms of CIPO selected from abnormal gastrointestinal motility, increased dilatation of the proximal colon and/or of the distal small intestine, modified intestinal contractility, ulceration, inflammation of the proximal colon and/or of the distal small intestine, pseudo-obstructive episode, vomiting, bloating, abdominal pain, mental health, quality of life and lethality is alleviated and/or ameliorated and/or wherein the number and/or frequency of CIPO-related and/or CIPO-caused hospitalizations is reduced.
8. The use of one of claims 1 to 6, wherein the medicament is to be administered in a dosage of 0.5 to 30 mg/day, preferably 5 to 15 mg/day, more preferably in a dosage of 15 mg/day based on the weight of the free base.
9. The use of one of claims 1 to 8, wherein the medicament is to be administered for a period of time of two to twelve weeks, preferably two to six weeks.
10. The use of one of claims 1 to 9, wherein the medicament is to be administered orally, parenterally, buccally, sublingually, rectally, intraperitoneally, or endotracheally.
11. The use of claim 10, wherein the percutaneous administration is subcutaneous, intramuscular, intravenous, transdermal, or by implantation.
12. The use of claim 10, wherein the medicament is to be administered orally in the form of a liquid, capsule, tablet, chewable tablet, dissolvable film, pill, lozenge, cachet, dragee, powder, granules, a solution, a suspension, an oil-in-water or water-in-oil liquid emulsion, an elixir or a syrup.
13. The use of claim 10, wherein the medicament is to be administered parentally in the form of a liquid, solid or gel.
14. The use of one of claims 1 to 13, wherein the medicament is to be taken orally with or without food, preferably in a once daily administration.